Inhibrx Biosciences INBX
NASDAQ INBX
$104.70 +2.99 (+2.94%)
As of: Sep 29, 2026 · 3:59 PM EDT

Inhibrx Biosciences (INBX) EBITDA (2023 - 2026)

Updated

Inhibrx Biosciences (INBX) posted EBITDA of -$31.63 million for Q2 2026, compared with -$26.73 million a year earlier.

Analysis

Inhibrx Biosciences (INBX) EBITDA (2023 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, EBITDA at Inhibrx Biosciences was -$121.94 million; for FY2025, it was -$132.54 million.

  • In prior years, Inhibrx Biosciences' EBITDA was -$329.16 million in FY2024 and -$218.03 million in FY2023.
  • Quarterly EBITDA has run from a low of -$160.42 million in Q2 2024 to a high of -$26.73 million in Q2 2025 over five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 9.10 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 8.33 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 999.00 Mn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 5.09 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 4.63 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -9.70 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 5.89 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 1.30 Bn
10 Inhibrx Biosciences 1.50 Bn 1.50 Bn - -31.63 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -31.63 Mn
Dec 31, 2025 -30.36 Mn
Sep 30, 2025 -33.23 Mn
Jun 30, 2025 -26.73 Mn
Mar 31, 2025 -42.23 Mn
Dec 31, 2024 -49.24 Mn
Sep 30, 2024 -46.04 Mn
Jun 30, 2024 -160.42 Mn
Mar 31, 2024 -73.47 Mn
Dec 31, 2023 -87.99 Mn
Sep 30, 2023 -45.52 Mn
Jun 30, 2023 -41.04 Mn
API Access

Inhibrx Biosciences EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda&ticker=INBX&period=max&api_key=YOUR_API_KEY